Apob Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| APOB — Apolipoprotein B |
|---|
| Protein Name | Apolipoprotein B |
| Gene | [APOB](/genes/apob) |
| UniProt ID | P04114 |
| PDB Structure | 1L2B, 1EQG |
| Molecular Weight | 515 kDa (APOB-100), 240 kDa (APOB-48) |
| Subcellular Localization | Secreted, plasma VLDL/LDL |
| Protein Family | Apolipoprotein B family |
APOB (Apolipoprotein B) is a protein encoded by a gene located on chromosome 2p24.1. This protein is involved in various cellular processes including gene expression regulation, signal transduction, and metabolic functions. APOB plays important roles in neuronal function and is implicated in neurodegenerative diseases.
APOB is one of the largest proteins in nature and serves as the structural protein of VLDL and LDL particles.
- APOB-100: Full-length (4563 aa), synthesized in liver
- APOB-48: Truncated (2152 aa), synthesized in intestine
¶ Domain Architecture
- Signal Peptide: Secretory signal
- N-terminal β-sheet: Lipid-binding, LDLR binding site (1-1700 aa)
- Central β-barrel domains: Multiple beta-sheet regions
- C-terminal amphipathic helices: Lipid-binding (3500-4563 aa)
- LDLR-binding region: Critical for LDL clearance
- Extremely large protein (one of the largest known)
- Multiple lipid-binding domains
- LDLR-binding site in N-terminal region
- Very low-density lipoprotein assembly domain
APOB is essential for lipid transport:
- VLDL Assembly: Structural protein for VLDL particles
- LDL Formation: APOB-100 remains on LDL after lipolysis
- Lipid Transport: Carries triglycerides, cholesterol
- LDL Receptor Binding: Mediates LDL uptake via LDLR
- Aβ Binding: Can bind amyloid-beta peptides
- Delivery of lipids from liver to peripheral tissues
- Maintenance of plasma cholesterol levels
- Lipid homeostasis
- APOB polymorphisms may modify AD risk
- Can bind and transport Aβ in circulation and brain
- APOB-Aβ complexes may influence neurodegeneration
- Elevated APOB is a major cardiovascular risk factor
- APOB > LDL is superior predictor of risk
- Familial hypercholesterolemia: APOB mutations cause disease
- Atherosclerosis driven by APOB-containing lipoproteins
- Hypertriglyceridemia with elevated APOB
- Insulin resistance association
- Obesity links
- Statins: Lower APOB levels
- PCSK9 inhibitors: Dramatically reduce APOB
- APOB synthesis inhibitors: In development
- APOB measurement for cardiovascular risk assessment
- APOB/LDL ratio for atherogenic particles
-
Sniderman AD, et al. (2014). "Apolipoprotein B vs LDL-C as markers." JAMA. PMID:25196643
-
Rader DJ, Hovingh GK. (2014). "Lipoprotein(a) and cardiovascular disease." Lancet. PMID:25253126
-
Koudinov A, et al. (1996). "Apolipoprotein B in Alzheimer's disease brain." Lancet. PMID:8709718
-
Yao X, et al. (2022). "APOB and Alzheimer's disease." J Alzheimer's Dis. PMID:35180145
The study of Apob Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- PMID:26437361 - Lipoprotein metabolism in neurodegeneration
- PMID:25997342 - Lipid transport in brain
- PMID:24668245 - Cholesterol and AD
- PMID:25009184 - Apolipoproteins in CNS
- PMID:26245252 - Lipid signaling in neurodegeneration